A study found LO2A resulted in a significant improvement of both subjective and objective symptoms of Sjögren’s syndrome-related dry eye disease, Wize Pharma announced in a press release.
The 21-patient prospective, unmasked study found LO2A significantly decreased the lid parallel conjunctival folds degree from 2.48 ± 0.75 on the right eye and 2.57 ± 0.75 on the left eye to 1.33 ± 0.73 and 1.38 ± 0.67, respectively, after 3 months, according to data presented in a poster at the Association for Research in Vision and Ophthalmology meeting. Initial
Uncategorized